SCIG in Focus: Equipping Clinicians for CIDP Care - January 2026

Clinical Edge: Standardized Supplies for SCIG Patients

This session will provide professionals with an overview of standardized supplies commonly used with SCIG patients.

1. Describe patient-specific characteristics used to guide product selection and, therefore, also SCIG supply selection.
2. Discuss patient assessment findings and how to integrate them into SCIG administration practices.
3. Review the importance of education and strategies for training.
4. Recognize the importance of multi-disciplinary collaboration, communication, and shared decision-making to optimize SCIG patient outcomes.

Clinical Connect: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This session will provide professionals with an overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the infusion therapies prescribed for treatment.

1. Describe the pathophysiology, typical clinical features, and initial diagnostic workup for CIDP, and outline treatment options.
2. Examine the current efficacy, safety, dosing, and administration of therapies for chronic inflammatory demyelinating polyneuropathy (CIDP).
3. Analyze best practices for the formulation transition of intravenous to subcutaneous immunoglobulin (IVIG to SCIG) among patients with CIDP.
4. Identify the role of specialty pharmacists in monitoring therapy, optimizing the management of patients, and how collaborating with the interdisciplinary team fosters continuity and safety in patient care and outcomes. 

Clinical Edge: A Case Study: Examining a Patient with CIDP on SCIG

This session will provide professionals with an immersive case study experience on a CIDP patient receiving SCIG.

1. Explain which CIDP patients are ideal candidates for SCIG therapy and important considerations to evaluate when switching from IVIG to SCIG therapy.
2. Discuss current SCIG efficacy and safety information, dosing, and administration for CIDP and how real-world data may differ.
3. Improve patient outcomes in CIDP by identifying risk factors and addressing challenges with SCIG therapy.

***Full front matter document will be attached for all 3 sessions